Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?

Most patients with non‐small cell lung cancer (NSCLC) harboring common epidermal growth factor receptor (EGFR) mutations, such as deletions in exon 19 or the L858R mutation in exon 21, respond dramatically to EGFR tyrosine kinase inhibitors (EGFR‐TKI), and their sensitivities to various EGFR‐TKI hav...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Sci
Hlavní autoři: Banno, Eri, Togashi, Yosuke, Nakamura, Yu, Chiba, Masato, Kobayashi, Yoshihisa, Hayashi, Hidetoshi, Terashima, Masato, de Velasco, Marco A., Sakai, Kazuko, Fujita, Yoshihiko, Mitsudomi, Tetsuya, Nishio, Kazuto
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2016
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4982590/
https://ncbi.nlm.nih.gov/pubmed/27240419
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12980
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky